PB101, a VEGF- and PlGF-targeting decoy protein, enhances antitumor immunity and suppresses tumor progression and metastasis

References

• Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358(19):2039–11. doi:10.1056/NEJMra0706596.
   PubMed Web of Science ®Google Scholar
• Augustin HG, Koh GY. Antiangiogenesis: vessel regression, vessel normalization, or both? Cancer Res. 2022;82(1):15–17. doi:10.1158/0008-5472.CAN-21-3515.
   PubMed Web of Science ®Google Scholar
• Lee WS, Yang H, Chon HJ, Kim C. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp Mol Med. 2020;52(9):1475–1485. doi:10.1038/s12276-020-00500-y.
   PubMed Web of Science ®Google Scholar
• Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15(5):325–340. doi:10.1038/nrclinonc.2018.29.
   PubMed Web of Science ®Google Scholar
• Kim C, Yang H, Fukushima Y, Saw P, Lee J, Park J-S, Park I, Jung J, Kataoka H, Lee D, et al. Vascular RhoJ is an effective and selective target for tumor angiogenesis and vascular disruption. Cancer Cell. 2014;25(1):102–117. doi:10.1016/j.ccr.2013.12.010.
   PubMed Web of Science ®Google Scholar
• Park J-S, Kim I-K, Han S, Park I, Kim C, Bae J, Oh SJ, Lee S, Kim JH, Woo D-C, et al. Normalization of tumor vessels by Tie2 activation and Ang2 inhibition enhances drug delivery and produces a favorable tumor microenvironment. Cancer Cell. 2016;30(6):953–967. doi:10.1016/j.ccell.2016.10.018.
   PubMed Web of Science ®Google Scholar
• Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009;15(3):232–239. doi:10.1016/j.ccr.2009.01.021.
   PubMed Web of Science ®Google Scholar
• Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D, Casanovas O, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15(3):220–231. doi:10.1016/j.ccr.2009.01.027.
   PubMed Web of Science ®Google Scholar
• Kim CW, Chon HJ, Kim C. Combination immunotherapies to overcome intrinsic resistance to checkpoint blockade in microsatellite stable colorectal cancer. Cancers. 2021;13(19):4906. doi:10.3390/cancers13194906.
   PubMed Web of Science ®Google Scholar
• Aguiar R, Moraes J. Exploring the immunological mechanisms underlying the anti-vascular endothelial growth factor activity in tumors. Front Immunol. 2019;10:1023. doi:10.3389/fimmu.2019.01023.
   PubMed Web of Science ®Google Scholar
• Khan KA, Kerbel RS. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol. 2018;15(5):310–324. doi:10.1038/nrclinonc.2018.9.
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, Kudo M, Breder V, Merle P, Kaseb AO, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745.
   PubMed Web of Science ®Google Scholar
• Motzer R, Alekseev B, Rha S-Y, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384(14):1289–1300. doi:10.1056/NEJMoa2035716.
   PubMed Web of Science ®Google Scholar
• Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116–1127. doi:10.1056/NEJMoa1816714.
   PubMed Web of Science ®Google Scholar
• Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–2301. doi:10.1056/NEJMoa1716948.
   PubMed Web of Science ®Google Scholar
• Makker V, Colombo N, Casado Herráez A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med. 2022;386(5):437–448. doi:10.1056/NEJMoa2108330.
   PubMed Web of Science ®Google Scholar
• Ribatti D. The discovery of the placental growth factor and its role in angiogenesis: a historical review. Angiogenesis. 2008;11(3):215–221. doi:10.1007/s10456-008-9114-4.
   PubMed Web of Science ®Google Scholar
• Albonici L, Giganti MG, Modesti A, Manzari V, Bei R. Multifaceted role of the placental growth factor (PlGF) in the antitumor immune response and cancer progression. Int J Mol Sci. 2019;20(12):2970. doi:10.3390/ijms20122970.
   PubMed Web of Science ®Google Scholar
• Selvaraj SK, Giri RK, Perelman N, Johnson C, Malik P, Kalra VK. Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. Blood. 2003;102(4):1515–1524. doi:10.1182/blood-2002-11-3423.
   PubMed Web of Science ®Google Scholar
• Cao Y. Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci Signal. 2009;2(59):re1–re1. doi:10.1126/scisignal.259re1.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Tu C, Zhao Y, Liu H, Zhang S. Placental growth factor enhances angiogenesis in human intestinal microvascular endothelial cells via PI3K/Akt pathway: potential implications of inflammation bowel disease. Biochem Bioph Res Co. 2016;470(4):967–974. doi:10.1016/j.bbrc.2016.01.073.
   PubMed Web of Science ®Google Scholar
• Snuderl M, Batista A, Kirkpatrick ND, Ruiz de Almodovar C, Riedemann L, Walsh E, Anolik R, Huang Y, Martin J, Kamoun W, et al. Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell. 2013;152(5):1065–1076. doi:10.1016/j.cell.2013.01.036.
   PubMed Web of Science ®Google Scholar
• He C, Zhu K, Bai X, Li Y, Sun D, Lang Y, Ning J, Sun F, Qu C, Xu S, et al. Placental growth factor mediates crosstalk between lung cancer cells and tumor-associated macrophages in controlling cancer vascularization and growth. Cell Physiol Biochem. 2018;47(6):2534–2543. doi:10.1159/000491650.
   PubMedGoogle Scholar
• Voron T, Colussi O, Marcheteau E, Pernot S, Nizard M, Pointet A-L, Latreche S, Bergaya S, Benhamouda N, Tanchot C, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med. 2015;212(2):139–148. doi:10.1084/jem.20140559.
   PubMed Web of Science ®Google Scholar
• Kim CG, Jang M, Kim Y, Leem G, Kim KH, Lee H, Kim T-S, Choi SJ, Kim H-D, Han JW, et al. VEGF-A drives TOX-dependent T cell exhaustion in anti–PD-1–resistant microsatellite stable colorectal cancers. Sci Immunol. 2019;4(41):eaay0555. doi:10.1126/sciimmunol.aay0555.
   PubMed Web of Science ®Google Scholar
• Shin J-Y, Yoon I-H, Kim J-S, Kim B, Park C-G. Vascular endothelial growth factor-induced chemotaxis and IL-10 from T cells. Cell Immunol. 2009;256(1–2):72–78. doi:10.1016/j.cellimm.2009.01.006.
   PubMed Web of Science ®Google Scholar
• Lee J-E, Kim C, Yang H, Park I, Oh N, Hua S, Jeong H, An HJ, Kim SC, Lee GM, et al. Novel glycosylated VEGF decoy receptor fusion protein, VEGF-Grab, efficiently suppresses tumor angiogenesis and ProgressionStructure-based design of novel antiangiogenic biologics. Mol Cancer Ther. 2015;14(2):470–479. doi:10.1158/1535-7163.MCT-14-0968-T.
   PubMed Web of Science ®Google Scholar
• Hong HK, Park YJ, Kim DK, Ryoo N-K, Ko Y-J, Park KH, Kim HM, Woo SJ. Preclinical efficacy and safety of VEGF-grab, a novel anti-VEGF drug, and its comparison to aflibercept. Invest Ophthalmol Visual Sci. 2020;61(13):22–22. doi:10.1167/iovs.61.13.22.
   PubMed Web of Science ®Google Scholar
• Park I, Yang H, Park J-S, Koh GY, Choi EK. VEGF-Grab enhances the efficacy of radiation therapy by blocking VEGF-A and treatment-induced PlGF. Int J Radiat Oncol. 2018;102(3):609–618. doi:10.1016/j.ijrobp.2018.06.401.
   PubMedGoogle Scholar
• Yang H, Lee WS, Kong SJ, Kim CG, Kim JH, Chang SK, Kim S, Kim G, Chon HJ, Kim C, et al. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade. J Clin Invest. 2019;129(10):4350–4364. doi:10.1172/JCI125413.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Yang H, Kim WR, Lee YS, Lee WS, Kong SJ, Lee HJ, Kim JH, Cheon J, Kang B, et al. STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer. J Immunother Cancer. 2021;9(6):e002195. doi:10.1136/jitc-2020-002195.
   PubMed Web of Science ®Google Scholar
• Park HS, Kim YM, Kim S, Lee WS, Kong SJ, Yang H, Kang B, Cheon J, Shin S-J, Kim C, et al. High endothelial venule is a surrogate biomarker for T-cell inflamed tumor microenvironment and prognosis in gastric cancer. J Immunother Cancer. 2021;9(10):e003353. doi:10.1136/jitc-2021-003353.
   PubMed Web of Science ®Google Scholar
• Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA. 2002;99(17):11393–11398. doi:10.1073/pnas.172398299.
   PubMed Web of Science ®Google Scholar
• Ciombor KK, Berlin J. Aflibercept—a decoy VEGF receptor. Curr Oncol Rep. 2014;16(2):1–7. doi:10.1007/s11912-013-0368-7.
   Web of Science ®Google Scholar
• Heier JS, Brown DM, Chong V, Korobelnik J-F, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537–2548. doi:10.1016/j.ophtha.2012.09.006.
   PubMed Web of Science ®Google Scholar
• Kim Y, Nam HJ, Lee J, Park DY, Kim C, Yu YS, Kim D, Park SW, Bhin J, Hwang D, et al. Methylation-dependent regulation of HIF-1α stability restricts retinal and tumour angiogenesis. Nat Commun. 2016;7(1):10347. doi:10.1038/ncomms10347.
   PubMedGoogle Scholar
• Maxwell PH, Wiesener MS, Chang G-W, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399(6733):271–275. doi:10.1038/20459.
   PubMed Web of Science ®Google Scholar
• Depoix C, Tee MK, Taylor RN. Molecular regulation of human placental growth factor (PlGF) gene expression in placental villi and trophoblast cells is mediated via the protein kinase a pathway. Reprod Sci. 2011;18(3):219–228. doi:10.1177/1933719110389337.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Juárez VM, Hsieh JJ, Basso U, Shah AY, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829–841. doi:10.1056/NEJMoa2026982.
   PubMed Web of Science ®Google Scholar
• Amin A, Plimack ER, Ernstoff MS, Lewis LD, Bauer TM, McDermott DF, Carducci M, Kollmannsberger C, Rini BI, Heng DYC, et al. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. J Immunotherapy Cancer. 2018;6(1):1–12. doi:10.1186/s40425-018-0420-0.
   PubMedGoogle Scholar
• Allen E, Jabouille A, Rivera LB, Lodewijckx I, Missiaen R, Steri V, Feyen K, Tawney J, Hanahan D, Michael IP, et al. Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation. science translational medicine. Sci Transl Med. 2017;9(385):eaak9679. doi:10.1126/scitranslmed.aak9679.
   PubMed Web of Science ®Google Scholar
• Schmittnaegel M, Rigamonti N, Kadioglu E, Cassará A, Wyser Rmili C, Kiialainen A, Kienast Y, Mueller H-J, Ooi C-H, Laoui D, et al. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. Sci Transl Med. 2017;9(385):eaak9670. doi:10.1126/scitranslmed.aak9670.
   PubMed Web of Science ®Google Scholar
• Lai X, Friedman A. How to schedule VEGF and PD-1 inhibitors in combination cancer therapy? BMC Syst Biol. 2019;13(1):1–18. doi:10.1186/s12918-019-0706-y.
   PubMedGoogle Scholar
• Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. BMB Rep. 2006;39(5):469–478. doi:10.5483/BMBRep.2006.39.5.469.
   Google Scholar
• Kim M, Park HJ, Seol JW, Jang JY, Cho Y-S, Kim KR, Choi Y, Lydon JP, DeMayo FJ, Shibuya M, et al. VEGF - A regulated by progesterone governs uterine angiogenesis and vascular remodelling during pregnancy. EMBO Mol Med. 2013;5(9):1415–1430. doi:10.1002/emmm.201302618.
   PubMed Web of Science ®Google Scholar
• Donnini S, Machein MR, Plate KH, Weich HA. Expression and localization of placenta growth factor and PlGF receptors in human meningiomas. J Pathol. 1999;189(1):66–71. doi:10.1002/(SICI)1096-9896(199909)189:1<66:AID-PATH390>3.0.CO;2-X.
   PubMed Web of Science ®Google Scholar